NEOVACS |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.98 EUR | -1.00% |
|
-1.00% | -1.00% |
| Sales 2021 | 22.54K 24.03K | Sales 2022 | 1.11K 1.19K | Capitalization | 116K 124K |
|---|---|---|---|---|---|
| Net income 2021 | -11M -11.73M | Net income 2022 | -3M -3.2M | EV / Sales 2021 | - |
| Net cash position 2021 | 32.06M 34.17M | Net cash position 2022 | 5.55M 5.92M | EV / Sales 2022 | - |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-
| Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0.12% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.00% |
NEOVACS has become a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. With its innovative technology inducing a polyclonal immune response, protected by four patent families potentially until 2038, NEOVACS focuses its clinical efforts on the development of IFN?-Kinoid for treating lupus. The group also carries out preclinical work on other therapeutic vaccines to treat autoimmune diseases, cancer, allergies and type 1 diabetes.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.82% | 41.35B | |
| +42.04% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- ALNEV Stock
- ALNEV Stock
